Amendment 2 to the Solicitation - Operate, Maintain and Improve the existing Proteomic Data Commons (PDC)

This Special Notice has been released to notify Offerors of an Amendment to Solicitation S23-072. This Special Notice is NOT to provide notice of a new Solicitation, but rather to update Offerors with Answers to Questions received regarding Solicitation S23-072. A Special Notice for the Leidos Biomedical Research “Request for Proposal (RFP) S23-072 to Maintain, Operate, and Improve the PDC” was previously posted to SAM.gov on May 16, 2023 . ( https://sam.gov/opp/cda50ba1ffb945e3b7505229a825b92f/view#general ) . A Special Notice for the Leidos Biomedical Research Solicitation, titled -“Amendment 1 to the Solicitation - Maintain, Operate, and Improve the PDC” was previously posted to SAM.gov on June 15, 2023. ( https://sam.gov/opp/4511197d408f41b0805a9135405ef75b/view ) Leidos Biomedical Research, Inc. (Leidos Biomed), a subsidiary of Leidos Corporation, a Delaware corporation with offices in Frederick, MD is the Operations and Technical Support (OTS) contractor for the National Cancer Institute at Frederick. The effort to be performed will be part of Leidos Biomed’s Prime Contract 75N91019D00024 that has been issued by the National Cancer Institute, National Institutes of Health, Frederick, MD. Description of Work - National Cancer Institute’s Proteomic Data Commons (PDC) is the largest public repository of comprehensive tumor proteomic datasets. It’s a cloud-based resource that collects, harmonizes, and hosts mass spectrometry-based proteomic data along with corresponding metadata across a variety of tumor types from programs including Clinical Proteomic Tumor Analysis Consortium (CPTAC), International Cancer Proteogenome Consortium (ICPC) and the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network. The PDC data portal is open access and provides end users with appropriate compute capacity to support large-scale analytical capabilities. PDC also maps datasets, when available, to corresponding genomic and/or imaging data within the NCI Cancer Research Data Commons (CRDC). Objectives - The objectives of Proteomic Data Commons (PDC) are (1) to make cancer-related proteomic datasets easily accessible to the public, and (2) to facilitate direct multi-omics integration in support of precision medicine through interoperability with accompanying data resources (such as genomic and medical image datasets). The scope of this Statement of Work (SOW) is to operate, maintain and improve the existing Proteomic Data Commons (PDC). The PDC has been available to the scientific community for over 3 years. It is part of the CRDC data ecosystem and is expected to utilize all the relevant CRDC interoperability requirements such as Cancer Data Aggregator. Areas influenced by these requirements include system design, PDC data model, data sharing, Application Programming Interfaces (APIs) and communication activities. Since the PDC has already completed development and has been released in a production environment, the main activities will be continued operations of PDC along with necessary enhancements due to the new data types (such as metabolomics) and to improve data utilization and interoperability.